In comedy, the more you can surprise the audience by subverting their expectations, the better. There is nothing better than coming up with a brilliant set piece, something that writers and actors can ...

In medieval Denmark, people could pay for more prestigious graves closer to the church — a sign of wealth and status. But when researchers examined hundreds of skeletons, they discovered something ...

Jeremy has more than 2300 published articles on Collider to his name, and has been writing for the site since February 2022. He's an omnivore when it comes to his movie-watching diet, so will gladly ...

Scientists may have spotted a long-sought triplet superconductor — a material that can transmit both electricity and electron spin with zero resistance. That ability could dramatically stabilize ...

CNBC's Jim Cramer explains why he is keeping an eye on shares of Grail and Coreweave. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to ...

Shares of early cancer-detection test maker Grail plunged 50% early Friday after a landmark U.K. study showed the test didn’t significantly reduce later-stage cancer cases. Grail said late Thursday ...

The biotech is developing a test to detect multiple cancers. However, a recent clinical trial did not produce the hoped-for results. The share price will likely remain low unless Grail has more ...

I discussed the game-changing event on Friday. Simply put, the company's trial of its Galleri multi-cancer early detection (MCED) with England's National Health Service (NHS) failed to meet its ...

GRAIL reiterated its guidance from January, projecting "Galleri sales growth of 22% to 32% and cash burn for the full year of 2026 to be no more than $300 million." Management stated, "Our cash runway ...

Feb 20 (Reuters) - Grail's (GRAL.O), opens new tab shares plunged nearly 50% on Friday after the company said routine screening with its cancer blood test failed to significantly boost early detection ...